VIMUGEN Immunoglobulin

Pharmacokinetics

• Immediately after intravenous administration, immunoglobulin is fully bioavailable in the patient's circulation.

• It distributes relatively quickly between plasma and extravascular fluid, with equilibrium between intravascular and extravascular compartments reached approximately 3 to 5 days after administration.

• The half-life of IgG is between 30 to 32 days. This half-life may vary in each patient, especially in primary immunodeficiencies.

• The catabolism of IgG and IgG complexes occurs in cells of the reticuloendothelial system.

Therapeutic Indications

• Agammaglobulinemias and congenital hypogammaglobulinemias

• Common variable immunodeficiency

• Severe combined immunodeficiency

• Wiskott-Aldrich syndrome

• Myeloma or chronic lymphocytic leukemia with severe secondary hypogammaglobulinemia and recurrent infections

• Children with congenital AIDS and recurrent infections

• Idiopathic thrombocytopenic purpura (ITP)

• Guillain-Barré syndrome

• Kawasaki disease

• Allogeneic bone marrow transplantation

Available Presentations

Composition